A Pilot Study
Glutathione
A preliminary clinical trial was conducted to evaluate the impact of liposomal glutathione on glutathione blood levels after two hours (N=4). Moreover, seven healthy members of the sample were given 750 mg of liposomal glutathione (CELLg8®) two times a day for a period of 30 days. There was a reduction in bilirubin and 39% decrease in blood mercury, representing better detoxification and liver function. Additionally, no other major changes were detected in the 21 blood panel tests apart from an enhancement in kidney and liver function. Further testing is in progress to increase the sample size to 12.
A Pilot Study
Absorption, Safety, and Detoxification Effects of Oral Liposomal Glutathione
Abstract
A pilot clinical study was undertaken to assess the effect of liposomal glutathione on blood levels and detoxification processes (N=2). Peak
Seven other healthy individuals took 750 mg of liposomal glutathione (CELLg8®) twice daily for 30 days. Improved detoxification and liver function was demonstrated by decreased bilirubin and 39% decreased blood mercury. All other indicators of the 21 blood panel remained healthy during the 30 days without any significant change.
Further testing is in processes to extend the study by an N of 12.
A pilot clinical study was undertaken to assess the effect of liposomal glutathione on glutathione blood levels after 2 hours (N=4).
Seven other healthy individuals took 750 mg of liposomal glutathione (CELLg8®) twice daily for 30 days. Improved detoxification and liver function was demonstrated by decreased bilirubin and 39% decreased blood mercury. All other indicators of the 21 blood panel remained healthy during the 30 days without any significant change other than a positive change for kidney and liver function.
Further testing is in processes to extend the study by an N of 12.
